GLAXOSMITHKLINE PLC Form 6-K January 12, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 12 January 2017

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Sir Andr	ew Witty	
b)	Position/status	Chief Ex	ecutive Officer	
c)	Initial notification/	Initial no	otification	
0)	amendment	miniai in	Juncation	
2.	Details of the issuer, emission allowance	e market p	participant, auction	
2.	platform, auctioneer or auction monitor			
a)	Name	GlaxoSn	nithKline plc	
b)	LEI	5493000	HZTVUYLO1D793	
	Details of the transaction(s): section to b	-		
3.	instrument; (ii) each type of transaction;		date; and (iv) each	
	place where transaction(s) has been conc			
		-	shares of 25 pence	
a)	Description of the financial instrument	each ('O	rdinary Shares')	
u)	Description of the influence instrument			
			B0009252882	
		-	ion of Ordinary Shares	
b)	Nature of the transaction		e Company's	
-)		ShareRe	ward Plan	
		D : ()	XX 1 ()	
		Price(s)	Volume(s)	
		615.06	Q (manter angle in ale angle)	
c)	Price(s) and volume(s)	£15.96	8 (partnership shares)	
		£15.96	8 (matching shares)	
		213.90	o (matching shares)	
	Aggregated information			
d)		16 Ordir	nary Shares	
	Aggregated volume Price	£15.96	and shares	
e)	Date of the transaction	2017-01	-11	
ź	Place of the transaction		Stock Exchange	
f)		(XLON)	-	
1.	Details of PDMR/person closely associa	ted with t	hem ('PCA')	
a)	Name	Ms E W	almsley	
b)	Position/status	CEO De	signate	
c)	Initial notification/	Initial no	otification	
C)	amendment	miniai m	Juncation	
2.	Details of the issuer, emission allowance	e market p	participant, auction	
	platform, auctioneer or auction monitor			
	Name		nithKline plc	
b)	LEI		HZTVUYLO1D793	
	Details of the transaction(s): section to b	-	• •	
3.	instrument; (ii) each type of transaction;	(iii) each	date; and (iv) each	

- place where transaction(s) has been conducted
- a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

		each (Oraniary Shares)	
b)	Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's ShareReward Plan	
		Price(s) Volume(s)	
c)	Price(s) and volume(s)	£15.96 8 (partnership shares)	
		£15.96 8 (matching shares)	
	Aggregated information		
d)	Aggregated volume Price	16 Ordinary Shares £15.96	
e)	Date of the transaction	2017-01-11	
f)	Place of the transaction	London Stock Exchange (XLON)	
1.	Details of PDMR/person closely associa	ted with them ('PCA')	
a)	Name	Mr R G Connor	
b)	Position/status	President, Global Manufacturing & Supply	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
,		Ordinary shares of 25 pence each ('Ordinary Shares')	
a)	Description of the financial instrument	ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan	
		Price(s) Volume(s)	
c)	Price(s) and volume(s)	£15.96 8 (partnership shares)	
,		£15.96 8 (matching shares)	

Aggregated information

1\			
d)	A game goted volume Dries	16 Ordinary Shares	
	Aggregated volume Price	£15.96	
e)	Date of the transaction	2017-01-11	
f)	Place of the transaction	London Stock Exchange	
1)		(XLON)	

1.	Details of PDMR/person closely associa	ted with t	hem ('PCA')
	Name	Mr S Di	ngemans
b)	Position/status	Chief Fi	nancial Officer
c)	Initial notification/ amendment	Initial no	otification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market p	participant, auction
	Name	GlaxoSmithKline plc	
b)	LEI		HZTVUYLO1D793
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each	•••
	prace where transaction(s) has been conc		shares of 25 pence
a)	Description of the financial instrument	-	rdinary Shares')
b)	Nature of the transaction	Acquisit under the	B0009252882 ion of Ordinary Shares e Company's ward Plan
		Price(s)	Volume(s)
c)	Price(s) and volume(s)	£15.96	8 (partnership shares)
		£15.96	8 (matching shares)
	Aggregated information	16 Ordir	ary Shares
d)	A service of a lower Dates	£15.96	lary shares
	Aggregated volume Price		
e)	Date of the transaction	2017-01	-11
f)	Place of the transaction		Stock Exchange
-)		(XLON)	
1.	Details of PDMR/person closely associa	ted with t	hem ('PCA')
	Name	Mr N Hi	
,	Position/status	-	obal Ethics &
0)	1 OSHIOH/SULLIS	Complia	nce

Initial notification

c) Initial notification/

amendment

\mathbf{r}	Details of the issuer,	emission allowa	ance market participant,	, auction
--------------	------------------------	-----------------	--------------------------	-----------

- 2. platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's ShareReward Plan
	Price(s) Volume(s)
c) Price(s) and volume(s)	£15.96 8 (partnership shares)
	£15.96 8 (matching shares)

Aggregated information d)

A garagated volume Drice	16 Ordinary Shares		
Aggregated volume Price	£15.96		
e) Date of the transaction	2017-01-11		
f) Place of the transaction	London Stock Exchange (XLON)		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr S A Hussain	
b)	Position/status	President, Global Pharmaceuticals	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance	e market participant, auction	
	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to b	e repeated for (i) each type of	
3.	instrument; (ii) each type of transaction;	(iii) each date; and (iv) each	
	place where transaction(s) has been cond	lucted	
	-	Ordinary shares of 25 pence	
a)	Description of the financial instrument	each ('Ordinary Shares')	
		ISIN: GB0009252882	
		Acquisition of Ordinary Shares	
b)	Nature of the transaction	under the Company's	

ShareReward Plan

		Edgar Filing	: GLAXO	DSMITHKLINE PLC - F
			Price(s)	Volume(s)
c)	Price(s) and volume(s)		£15.96	8 (partnership shares)
			£15.96	8 (matching shares)
1)	Aggregated information			
d)	Aggregated volume Price		16 Ordin £15.96	nary Shares
e)	Date of the transaction		2017-01	
f)	Place of the transaction		London (XLON)	Stock Exchange
1.	Details of PDMR/person cl	osely associa		
	Name Position/status		Mr D S I Chief St	Redfern rategy Officer
,	Initial notification/			
c)	amendment			otification
2.	Details of the issuer, emissi platform, auctioneer or auc		-	-
	Name LEI			nithKline plc HZTVUYLO1D793
í	Details of the transaction(s) instrument; (ii) each type of place where transaction(s) l	f transaction;	e repeated (iii) each lucted	d for (i) each type of
a)	Description of the financial	instrument	each ('O	rdinary Shares')
b)	Nature of the transaction		Acquisit under the	B0009252882 ion of Ordinary Shares e Company's ward Plan
			Price(s)	Volume(s)
c)	Price(s) and volume(s)		£15.96	8 (partnership shares)
			£15.96	8 (matching shares)
1\	Aggregated information			
d)	Aggregated volume Price	d volume Price 16 Ordinar £15.96		nary Shares
e)	Date of the transaction		2017-01	-11
f)	Place of the transaction		London (XLON)	Stock Exchange

		,		
a)	Name	Ms C Thomas		
b)	Position/status	SVP, Human Resources		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction		
a) b)				
,	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each			
	place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')		
		ISIN: GB0009252882		
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan		
		Price(s) Volume(s)		
c)	Price(s) and volume(s)	£15.96 8 (partnership shares)		
		£15.96 8 (matching shares)		
1\	Aggregated information			
d)	Aggregated volume Price	16 Ordinary Shares £15.96		
e)	Date of the transaction	2017-01-11		
f)	Place of the transaction	London Stock Exchange (XLON)		
	Details of PDMR/person closely associa Name	ted with them ('PCA') Mr P C Thomson		
a)		SVP, Communications &		
b)	Position/status	Government Affairs		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a) b)	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each		
		Ordinary shares of 25 pence		
a)	Description of the financial instrument	each ('Ordinary Shares')		
		ICINI. CD0000250000		

ISIN: GB0009252882

b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan		
		Price(s) Volume(s)		
c)	Price(s) and volume(s)	£15.96 8 (partnership shares)		
		£15.96 8 (matching shares)		
	Aggregated information			
d)	Aggregated volume Price	16 Ordinary Shares £15.96		
e)	Date of the transaction	2017-01-11		
f)	Place of the transaction	London Stock Exchange (XLON)		
	Details of PDMR/person closely associa Name	ted with them ('PCA') Dr P J T Vallance		
	Position/status	President, R&D		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction			
	platform, auctioneer or auction monitor Name	GlaxoSmithKline plc		
b)	LEI Details of the transaction(s): section to b	5493000HZTVUYLO1D793		
3.	instrument; (ii) each type of transaction;	(iii) each date; and (iv) each		
	place where transaction(s) has been cond	ducted Ordinary shares of 25 pence		
a)	Description of the financial instrument	each ('Ordinary Shares')		
		ISIN: GB0009252882		
		Acquisition of Ordinary Shares under the Company's		
b)	Nature of the transaction	ShareReward Plan		
		Price(s) Volume(s)		
c)	Price(s) and volume(s)	£15.96 8 (partnership shares)		
		£15.96 8 (matching shares)		
	Aggregated information			
d)	Aggregated volume Price	16 Ordinary Shares		
e)	Date of the transaction	£15.96 2017-01-11		
f)	Place of the transaction			

London Stock Exchange (XLON)

	Details of PDMR/person closely associa		
a)	Name	Mrs V A	•
b)	Position/status	Compan	y Secretary
c)	Initial notification/ amendment	Initial no	otification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market p	participant, auction
a)	Name	GlaxoSn	nithKline plc
	LEI		HZTVUYLO1D793
0)	Details of the transaction(s): section to b		
3	instrument; (ii) each type of transaction;	-	
5.	place where transaction(s) has been cond		date, and (IV) caen
	place where transaction(s) has been conc		v shares of 25 pence
		•	rdinary Shares')
a)	Description of the financial instrument	cach (O	runnary Shares)
			B0009252882 ion of Ordinary Shares
		-	e Company's
b)	Nature of the transaction		ward Plan
		Shareke	walu Flaii
		Price(s)	Volume(s)
c)	Price(s) and volume(s)	£15.96	8 (partnership shares)
		£15.96	8 (matching shares)
	Aggregated information		
d)	riggiegated information		
u)	Aggregated volume Price	16 Ordin	nary Shares
	Aggregated volume Flice	£15.96	
e)	Date of the transaction	2017-01	-11
Ð	Place of the transaction	London	Stock Exchange
f)		(XLON)	-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised. GlaxoSmithKline plc (Registrant)

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc